OA12631A - Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés. - Google Patents

Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés. Download PDF

Info

Publication number
OA12631A
OA12631A OA1200300333A OA1200300333A OA12631A OA 12631 A OA12631 A OA 12631A OA 1200300333 A OA1200300333 A OA 1200300333A OA 1200300333 A OA1200300333 A OA 1200300333A OA 12631 A OA12631 A OA 12631A
Authority
OA
OAPI
Prior art keywords
denotes
carbon atoms
heteroaryl
phenyl
alkyl
Prior art date
Application number
OA1200300333A
Other languages
English (en)
French (fr)
Inventor
Joachim Brendel
Thomas Boehme
Stefan Peukert
Heinz-Werner Kleemann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of OA12631A publication Critical patent/OA12631A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
OA1200300333A 2001-06-12 2002-05-21 Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés. OA12631A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
OA12631A true OA12631A (fr) 2006-06-14

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300333A OA12631A (fr) 2001-06-12 2002-05-21 Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés.

Country Status (41)

Country Link
US (2) US6903216B2 (ja)
EP (1) EP1399423B9 (ja)
JP (1) JP4422477B2 (ja)
KR (1) KR100863924B1 (ja)
CN (1) CN1247544C (ja)
AR (1) AR036045A1 (ja)
AT (1) ATE378318T1 (ja)
AU (1) AU2002316939B2 (ja)
BG (1) BG108415A (ja)
BR (1) BR0210374A (ja)
CA (1) CA2450076C (ja)
CO (1) CO5540283A2 (ja)
CR (1) CR7140A (ja)
CY (1) CY1107427T1 (ja)
CZ (1) CZ20033361A3 (ja)
DE (2) DE10128331A1 (ja)
DK (1) DK1399423T3 (ja)
EC (1) ECSP034883A (ja)
EE (1) EE05196B1 (ja)
ES (1) ES2295360T3 (ja)
HK (1) HK1065316A1 (ja)
HR (1) HRP20031028A2 (ja)
HU (1) HUP0400159A3 (ja)
IL (2) IL159247A0 (ja)
MA (1) MA27037A1 (ja)
MX (1) MXPA03010875A (ja)
MY (1) MY138341A (ja)
NO (1) NO20035450D0 (ja)
NZ (1) NZ530081A (ja)
OA (1) OA12631A (ja)
PE (1) PE20021066A1 (ja)
PL (1) PL364371A1 (ja)
PT (1) PT1399423E (ja)
RS (1) RS97703A (ja)
RU (1) RU2293727C2 (ja)
SK (1) SK15222003A3 (ja)
TN (1) TNSN03134A1 (ja)
TW (1) TWI304400B (ja)
UA (1) UA75412C2 (ja)
WO (1) WO2002100825A2 (ja)
ZA (1) ZA200308520B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
PL372936A1 (en) * 2002-04-26 2005-08-08 Ishihara Sangyo Kaisha, Ltd. Pyridine compounds or salts thereof and herbicides containing the same
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
SI1651621T1 (sl) 2003-08-08 2008-12-31 Janssen Pharmaceutica Nv 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
MX2007003623A (es) * 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
AU2007245891B2 (en) * 2006-04-27 2012-10-18 Sanofi-Aventis Deutschland Gmbh Inhibitors of the TASK-1 and TASK-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
NZ597379A (en) * 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
ES2416071T3 (es) * 2009-06-29 2013-07-30 Merz Pharma Gmbh & Co. Kgaa Método para preparar 1-amino-1,3,3,5,5-pentametilciclohexano
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (ja) 2011-07-01 2018-04-28
AU2013203252B2 (en) 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
KR20200042906A (ko) * 2017-08-07 2020-04-24 고쿠리츠다이가쿠호진 히로시마다이가쿠 신규 안트라닐산계 화합물, 및 이것을 사용한 Pin1 저해제, 염증성 질환의 치료제 및 암의 치료제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118595A (zh) 1993-12-27 1996-03-13 卫材株式会社 氨茴酸衍生物
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
DK1095016T3 (da) 1998-07-08 2006-03-13 Sanofi Aventis Deutschland Svovlsubstituerede sulfonylaminocarboxylsyre-N-arylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater omfattende dem
EP1109544A4 (en) * 1998-09-01 2004-10-27 Bristol Myers Squibb Co POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE
US6458845B1 (en) * 1999-06-24 2002-10-01 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
EP1399423A2 (de) 2004-03-24
US6903216B2 (en) 2005-06-07
CR7140A (es) 2004-04-15
ATE378318T1 (de) 2007-11-15
US20050137200A1 (en) 2005-06-23
DK1399423T3 (da) 2008-03-17
KR100863924B1 (ko) 2008-10-17
ECSP034883A (es) 2004-01-28
TWI304400B (en) 2008-12-21
WO2002100825A3 (de) 2003-12-11
EP1399423B1 (de) 2007-11-14
UA75412C2 (en) 2006-04-17
US7235664B2 (en) 2007-06-26
EP1399423B9 (de) 2008-02-27
CY1107427T1 (el) 2012-12-19
HUP0400159A2 (hu) 2004-07-28
MXPA03010875A (es) 2004-02-17
HRP20031028A2 (en) 2005-10-31
DE10128331A1 (de) 2002-12-19
EE05196B1 (et) 2009-08-17
NO20035450D0 (no) 2003-12-08
WO2002100825A2 (de) 2002-12-19
BR0210374A (pt) 2004-07-13
CZ20033361A3 (cs) 2004-05-12
MA27037A1 (fr) 2004-12-20
EE200300558A (et) 2004-02-16
JP2004533464A (ja) 2004-11-04
SK15222003A3 (sk) 2004-06-08
AR036045A1 (es) 2004-08-04
RU2293727C2 (ru) 2007-02-20
ZA200308520B (en) 2004-09-06
CN1529695A (zh) 2004-09-15
RU2004100302A (ru) 2005-04-10
HUP0400159A3 (en) 2008-10-28
CO5540283A2 (es) 2005-07-29
CN1247544C (zh) 2006-03-29
ES2295360T3 (es) 2008-04-16
RS97703A (en) 2006-12-15
PT1399423E (pt) 2008-02-07
HK1065316A1 (en) 2005-02-18
CA2450076A1 (en) 2002-12-19
TNSN03134A1 (en) 2005-12-23
BG108415A (en) 2004-07-30
US20030114499A1 (en) 2003-06-19
JP4422477B2 (ja) 2010-02-24
PE20021066A1 (es) 2003-01-21
IL159247A (en) 2010-06-16
DE50211213D1 (de) 2007-12-27
KR20040030668A (ko) 2004-04-09
CA2450076C (en) 2010-11-30
AU2002316939B2 (en) 2006-11-23
NZ530081A (en) 2005-07-29
PL364371A1 (en) 2004-12-13
IL159247A0 (en) 2004-06-01
MY138341A (en) 2009-05-29

Similar Documents

Publication Publication Date Title
OA12631A (fr) Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés.
JP7519221B2 (ja) 置換ピラゾロ[1,5-a]ピリミジンおよび医療疾患の治療におけるその使用
CN110719902B (zh) Ssao抑制剂
RU2283833C2 (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
JP4426660B2 (ja) ピラゾール誘導体、その製法および医薬としてのその使用
JP4527918B2 (ja) インダニル置換ベンゼンカルボキサミド、その製造方法、薬剤としてのその使用およびそれを含有する医薬処方物
TWI242005B (en) Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
JP5043645B2 (ja) カルボン酸
JPWO2012124744A1 (ja) 含窒素縮合複素環化合物
CN100497314C (zh) 取代的4-苯基四氢异喹啉、其制备方法、其用作药物的用途以及含有它们的药物
EP2771332B1 (en) Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
CN110357789A (zh) 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
JP2010527986A (ja) スピロ環状キナゾリン誘導体およびpde7阻害剤としてのその使用
JP2558208B2 (ja) インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
JPH01104038A (ja) アラルキルアミノアルコキシフェニル誘導体、その製法およびそれを含有する組成物
JP2006513222A (ja) アドレナリン性β受容体およびホスホジエステラーゼに対する抑制活性を有する強心性化合物
AU2015247575C1 (en) Polycyclic hERG activators
WO2004011470A1 (ja) フロイソキノリン誘導体およびその用途
JPH0859458A (ja) インダン誘導体を含有する高脂血症治療剤
EP0382628B1 (fr) Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
BR112017009276B1 (pt) Pirazolo[1,5-a]pirimidinas substituídas, composição farmacêutica e seus usos
MXPA98001121A (en) Compositions replaced with sulfonamide, procedure for its preparation, its employment as a diagnostic medicine or agent as well as a medicine that conti